Eureka Therapeutics, Inc.

Invisishield Technologies Ltd.

Zhiyuan Yang

Hong Liu

Cheng Liu

Lucas Horan

Jingwei Lu

Yiyang Xu

Su Yan

Vivien Wai-Fan Chan

Hongbing Zhang

Li Long

Lianxing Liu

Ziyou Cui

Guangyan Xiong

Neal Cheng

Jinyun Chen

Warner Greene

Jingyi Xiang

Pengbo Zhang

Hongruo Yun

Javier Morales

Shan Li

Jianying Liu

Xiaomei Ge

Yixiang Xu

Motao Liu

Lu Jin

Jingbao Liu

The present application provides chimeric proteins comprising an antibody moiety that specifically binds to a component of an influenza virus or a variant thereof, and a positively charged mucoadhesive peptide fragment. Compositions comprising the chimeric proteins described herein are useful for preventing or treating an infection caused by an influenza virus or a variant thereof in an individual.

Chimeric protein comprising an anti-influenza virus antibody moiety and a mucoadhesive peptide fragment for preventing or treating influenza infections

The present application relates to compositions for preventing or treating infections. In some embodiments, the present application provides chimeric proteins comprising a target-binding moiety comprising an extracellular binding domain (EBD) of an angiotensin-converting enzyme 2 (ACE2) protein or a fragment thereof that specifically binds to an S protein, and a positively charged mucoadhesive peptide fragment. Compositions comprising the chimeric proteins described herein are useful for preventing or treating a viral infection in an individual, such as a coronavirus infection.

Compositions for preventing or treating coronavirus infections

The present application provides constructs comprising an antibody moiety that specifically binds to PSMA (e.g., PSMA expressed on the surface of a cell). Also provided are methods of making and using these constructs.

Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof

Described herein are human antibody agents and multi-specific binding agents that specifically bind human CD 19, in particular, native human CD 19. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by CD 19 expression, in particular, B cell lymphomas and leukemias.

Antibody agents specific for human CD19 and uses thereof

The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module. Also provided are methods of making and using these constructs.

Antibody/T-cell receptor chimeric constructs and uses thereof

The present application provides chimeric antibody-TCR constructs comprising an antigen-binding module that specifically binds to a target antigen and a T cell receptor module capable of recruiting at least one TCR-associated signaling molecule. Also provided are methods of making and using these constructs.

Chimeric antibody/T-cell receptor constructs and uses thereof

The present application relates to compositions for preventing or treating viral and other microbial infections. In some embodiments, the present application provides chimeric proteins comprising a target-binding moiety that specifically binds to a pathogen that infects through a mucosa, and a positively charged mucoadhesive peptide fragment. Also provided are antibodies and constructs thereof that specifically binds to an S1 subunit of a spike protein of SARS-CoV-2. Compositions comprising the chimeric proteins, antibodies, or constructs described herein are useful for preventing or treating a microbial infection in an individual, such as a coronavirus infection.

Compositions for preventing or treating viral and other microbial infections

Growing community of inventors

Albany, CA, United States of America

Zhiyuan Yang